Company Filing History:
Years Active: 2023-2025
Title: David A. Hildeman: Innovator in Immune Response Modulation
Introduction
David A. Hildeman is a notable inventor based in Cincinnati, OH (US). He has made significant contributions to the field of immunology, particularly in the development of compounds that modulate immune responses. With a total of 3 patents, Hildeman's work focuses on innovative therapeutic approaches to treat inflammation-related diseases.
Latest Patents
Hildeman's latest patents include groundbreaking research on compounds useful for inhibiting BFL1 and their application in therapy. The first patent discloses compounds of Formula I and their use in methods of modulating an immune response by inhibiting BFL1. This research is particularly relevant for treating and preventing diseases characterized by inflammation, especially those induced by neutrophils. The second patent outlines methods of attenuating an immune response through the inhibition of BFL1, further emphasizing the potential for treating inflammation-related disorders.
Career Highlights
David A. Hildeman is affiliated with the Children's Hospital Medical Center, where he continues to advance his research in immunology. His work has garnered attention for its potential impact on therapeutic strategies for inflammatory diseases.
Collaborations
Hildeman collaborates with esteemed colleagues such as Suhas G. Kallapur and Jarek Meller, contributing to a dynamic research environment focused on innovative solutions in healthcare.
Conclusion
David A. Hildeman's contributions to the field of immunology through his patents and research at the Children's Hospital Medical Center highlight his commitment to advancing medical science. His work in inhibiting BFL1 represents a significant step forward in the treatment of inflammation-related diseases.